The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

[1]  Gao Hai-feng,et al.  Proliferation marker Ki-67 in early breast cancer , 2009 .

[2]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[3]  M. Gilcrease,et al.  Ki-67 as Prognostic Marker in Early Breast Cancer: A Meta-analysis of Published Studies Involving 12 155 Patients , 2008 .

[4]  J. Ahn,et al.  Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer , 2008, Cancer Chemotherapy and Pharmacology.

[5]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[6]  Robin L. Jones,et al.  Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. , 2006, The Lancet. Oncology.

[7]  D. Berry.  Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .

[8]  N. Funata,et al.  A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. , 2004, International journal of oncology.

[9]  A. Vincent-Salomon,et al.  Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. , 2004, European journal of cancer.

[10]  A. Schneeweiss,et al.  Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy , 2004, Anti-cancer drugs.

[11]  M. Dowsett,et al.  Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy , 1998, Breast Cancer Research and Treatment.

[12]  M. Dowsett,et al.  Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer , 2003, British Journal of Cancer.

[13]  F. Penault-Llorca,et al.  Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. , 2003, International journal of oncology.

[14]  M. J. van de Vijver,et al.  Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.

[15]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[16]  P. Bruzzi,et al.  Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer , 2001, British Journal of Cancer.

[17]  M G Daidone,et al.  Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer , 1999, International journal of cancer.

[18]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[19]  L. Skoog,et al.  Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. , 1999, Acta oncologica.

[20]  G. Giaccone,et al.  Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. , 1998, British Journal of Cancer.

[21]  M. Indelli,et al.  MIB-1 proliferative activity in invasive breast cancer measured by image analysis. , 1996, Journal of clinical pathology.

[22]  M. Brizzi,et al.  Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. , 1996, Anticancer research.

[23]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.